Welcome to LookChem.com Sign In|Join Free

CAS

  • or

159451-66-8

Post Buying Request

159451-66-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

159451-66-8 Usage

General Description

2-(N-BOC-AMINO)-5-BROMOPYRIDINE is a chemical compound that contains a pyridine ring with a bromine atom and a BOC-protected amino group. The BOC group, or tert-butoxycarbonyl, is commonly used as a protecting group for amines in organic synthesis. 2-(N-BOC-AMINO)-5-BROMOPYRIDINE is often used in the pharmaceutical industry as a building block for the synthesis of various biologically active molecules, such as potential drug candidates. The presence of the BOC-protected amino group allows for specific chemical reactions to be performed without affecting the amine functionality, making it a valuable intermediate in drug development and other chemical synthesis processes.

Check Digit Verification of cas no

The CAS Registry Mumber 159451-66-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,4,5 and 1 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 159451-66:
(8*1)+(7*5)+(6*9)+(5*4)+(4*5)+(3*1)+(2*6)+(1*6)=158
158 % 10 = 8
So 159451-66-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H13BrN2O2/c1-10(2,3)15-9(14)13-8-5-4-7(11)6-12-8/h4-6H,1-3H3,(H,12,13,14)

159451-66-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (646385)  2-(Boc-amino)-5-bromopyridine  97%

  • 159451-66-8

  • 646385-5G

  • 831.87CNY

  • Detail
  • Aldrich

  • (646385)  2-(Boc-amino)-5-bromopyridine  97%

  • 159451-66-8

  • 646385-5G

  • 831.87CNY

  • Detail
  • Aldrich

  • (646385)  2-(Boc-amino)-5-bromopyridine  97%

  • 159451-66-8

  • 646385-5G

  • 831.87CNY

  • Detail
  • Aldrich

  • (646385)  2-(Boc-amino)-5-bromopyridine  97%

  • 159451-66-8

  • 646385-5G

  • 831.87CNY

  • Detail

159451-66-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name tert-butyl N-(5-bromopyridin-2-yl)carbamate

1.2 Other means of identification

Product number -
Other names N-Boc-2-Amino-5-bromopyridine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:159451-66-8 SDS

159451-66-8Relevant articles and documents

Synthesis of [N-methyl- 11C]-3-[(6-dimethylamino)pyridin-3-yl]-2,5-dimethyl-N, N-dipropylpyrazolo[1,5-a]pyrimidine-7-amine: A potential PET ligand for in vivo imaging of CRF1 receptors

Kumar, J.S. Dileep,Majo, Vattoly J.,Prabhakaran, Jaya,Simpson, Norman R.,Van Heertum, Ronald L.,John Mann

, p. 1055 - 1065 (2003)

A convenient synthesis of [N-methyl- 11C]-3-[(6-dimethylamino)pyridin-3-yl]-2,5-dimethyl-N, N-dipropylpyrazolo[1,5-a]pyrimidine-7-amine (R121920), a highly selective CRF1 antagonist has been developed as a potential PET ligand. 3-[(6-methylamino)pyridin-3-yl]-2,5-dimethyl-N,N-dipropylpyrazolo [1,5-a]pyrimidine-7-amine (7), the precursor for radiolabelling was synthesized through a novel palladium catalyzed Suzuki coupling of aryl bromide 5 with heteroaryl boronate ester 4. The requisite boronate ester 4 was synthesized in four steps from 2-amino-4-bromopyridine in 50% overall yield. Although the synthesis of cold R121920 proceeded in 93% yield by sodium hexamethyl-disilazide (NaHMDS) mediated N-methylation of the desmethylamine 7 at -78°C, the attempted radiosynthesis under various conditions using conventional bases were not successful. However, the radiolabeling of [ 11C]R121920 was successfully carried out with [11C]MeOTf in acetone at -20°C in the absence of added basic reagents. The radiotracer was purified by RP-HPLC followed by RP-solid phase extraction. The yield of the reaction was 5% (at EOB) and the specific activity was > 1000 Ci/mmol (at EOB) with a radiochemical purity > 99%. Copyright

MRGPRX2 ANTAGONISTS AND USES THEREOF

-

Paragraph 00282-00283, (2021/05/15)

The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically or orally acceptable carrier for administration.

Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS

Schenck Eidam, Hilary,Russell, John,Raha, Kaushik,Demartino, Michael,Qin, Donghui,Guan, Huiping Amy,Zhang, Zhiliu,Zhen, Gong,Yu, Haiyu,Wu, Chengde,Pan, Yan,Joberty, Gerard,Zinn, Nico,Laquerre, Sylvie,Robinson, Sharon,White, Angela,Giddings, Amanda,Mohammadi, Ehsan,Greenwood-Van Meerveld, Beverly,Oliff, Allen,Kumar, Sanjay,Cheung, Mui

supporting information, p. 623 - 628 (2018/07/25)

Abdominal pain and abnormal bowel habits represent major symptoms for irritable bowel syndrome (IBS) patients that are not adequately managed. Although the etiology of IBS is not completely understood, many of the functions of the gastrointestinal (GI) tract are regulated by the enteric nervous system (ENS). Inflammation or stress-induced expression of growth factors or cytokines may lead to hyperinnervation of visceral afferent neurons in GI tract and contribute to the pathophysiology of IBS. Rearranged during transfection (RET) is a neuronal growth factor receptor tyrosine kinase critical for the development of the ENS as exemplified by Hirschsprung patients who carry RET loss-of-function mutations and lack normal colonic innervation leading to colonic obstruction. Similarly, RET signaling in the adult ENS maintains neuronal function by contributing to synaptic formation, signal transmission, and neuronal plasticity. Inhibition of RET in the ENS represents a novel therapeutic strategy for the normalization of neuronal function and the symptoms of IBS patients. Herein, we describe our screening effort and subsequent structure-activity relationships (SARs) in optimizing potency, selectivity, and mutagenicity of the series, which led to the discovery of a first-in-class, gut-restricted RET kinase inhibitor, 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide (15, GSK3179106), as a clinical candidate for the treatment of IBS. GSK3179106 is a potent, selective, and gut-restricted pyridone hinge binder small molecule RET kinase inhibitor with a RET IC50 of 0.3 nM and is efficacious in vivo.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 159451-66-8